Remove Clinical Trials Remove Genotoxicity Remove Nurses Remove Research
article thumbnail

FIRST-LINE IBRANCEĀ® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER

The Pharma Data

These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. However, this observational analysis differs from the randomized clinical trial in several ways.

HR 52
article thumbnail

PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027

The Pharma Data

Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants.

HR 52
article thumbnail

Let's Quit Sugar With Audiobook ā€“ Let's Quit Sugar

The Pharma Data

Experimental Diabetes Research. Effects of almond consumption on the reduction of LDL-cholesterol: a discussion of potential mechanisms and future research directions. Exposure to sorbitol during lactation causes metabolic alterations and genotoxic effects in rat offspring. DOI: 10.1016/j.reprotox.2014.09.007. 2014.09.007.

Insulin 52